Table 2.
Treatment-related adverse eventsa
| Adverse event | No. (%) of patients (N = 6) |
|---|---|
| ALT increased | 3 (50.0) |
| AST increased | 2 (33.3) |
| Hemoglobin decreased | 2 (33.3) |
| Decreased appetite | 2 (33.3) |
| Epistaxis | 2 (33.3) |
| Angina pectoris | 1 (16.7) |
| Conjuctival hemorrhage | 1 (16.7) |
| Eye pain | 1 (16.7) |
| Mouth hemorrhage | 1 (16.7) |
| Nausea | 1 (16.7) |
| Fatigue | 1 (16.7) |
| Pain | 1 (16.7) |
| Liver disorder | 1 (16.7) |
| Blood albumin decreased | 1 (16.7) |
| Blood alkaline phosphatase increased | 1 (16.7) |
| Blood glucose increased | 1 (16.7) |
| Blood magnesium increased | 1 (16.7) |
| Blood sodium increased | 1 (16.7) |
| Platelet count decreased | 1 (16.7) |
| WBC count decreased | 1 (16.7) |
| Headache | 1 (16.7) |
| Depression | 1 (16.7) |
| Dyspnea | 1 (16.7) |
| Pleural effusion | 1 (16.7) |
| Hemorrhage | 1 (16.7) |
ALT alanine aminotransferase; AST aspartate aminotransferase; WBC white blood cell
aRelated is defined as possibly, probably, or definitely related to study drug